Showing 111-120 of 2123 results for "".
Keep the Insurance Profit, Reduce Taxes, Protect Assets: Own Your Own Insurance Company
https://practicalneurology.com/columns/practice-management/keep-the-insurance-profit-reduce-taxes-protect-assets-own-your-own-insurance-company/30716/- No Strings Attached: Is It Time to Sever Your Ties With Insurers?https://practicalneurology.com/columns/practice-management/no-strings-attached-is-it-time-to-sever-your-ties-with-insurers/31234/Navigating Medicare Reimbursement Cuts: The Shift Towards Cash-Only Practices in NeurologyThe December 2006 issue of *Practical Neurology* explores the profound effects of impending Medicare reimbursement reductions on neurologists. With a mandated five percent across-the-board cut effective in 2007
- How Behavioral Headache Treatments Can Help You Fine-Tune Outcomeshttps://practicalneurology.com/diseases-diagnoses/headache-pain/PN1005Behavioral-pdf/31383/Integrating Behavioral Therapies in Headache Management: Enhancing Patient OutcomesPrimary headaches, including migraines and tension-type headaches, are prevalent neurological conditions traditionally managed with pharmacologic treatments. While these medications are effective for many patients, th
Epilepsy Essentials: Novel Interictal Biomarkers for Delineating the Epileptogenic Zone in Children With Drug-Resistant Epilepsy
https://practicalneurology.com/programs/practical-neurology-focus-on-epilepsy-seizures/epilepsy-essentials-novel-interictal-biomarkers-for-delineating-the-epileptogenic-zone-in-children-with-drug-resistant-epilepsy/32147/Novel interictal biomarkers of epilepsy are able to identify the epileptogenic zone with precision and predict surgical outcome in children with drug-resistant epilepsy.The Immune Stroke Spectrum: Navigating Inflammatory Cerebrovascular Disorders
https://practicalneurology.com/diseases-diagnoses/stroke/the-immune-stroke-spectrum-navigating-inflammatory-cerebrovascular-disorders/49163/This review provides a concise overview of commonly encountered inflammatory cerebrovascular disorders, highlighting their clinical features, diagnostic challenges, and treatment strategies, and emphasizing that despite their complexity, early recognition and systematic management often lead to fSurgical Evaluation and Treatment for Genetic Epilepsies
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/surgical-evaluation-and-treatment-for-genetic-epilepsies/32053/Genetic diagnosis can be useful in guiding surgical options for genetic epilepsies.Diagnosis and Management of Dementia and Psychosis in Individuals With Parkinson Disease
https://practicalneurology.com/diseases-diagnoses/movement-disorders/diagnosis-and-management-of-dementia-and-psychosis-in-individuals-with-parkinson-disease/37654/A review highlighting the clinical features of dementia and psychosis in people with Parkinson disease and diagnostic and therapeutic strategies for the management of these conditions.An Algorithmic Approach to Headache With Fever
https://practicalneurology.com/diseases-diagnoses/headache-pain/an-algorithmic-approach-to-headache-with-fever/54600/Headache accompanied by fever can indicate a wide range of disorders, making prompt and comprehensive evaluation crucial to identify the underlying cause and guide appropriate management for better patient outcomes.Relapse Management in Multiple Sclerosis: Corticosteroids Remain the Linchpin of Therapies
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/relapse-management-in-multiple-sclerosis-corticosteroids-remain-the-linchpin-of-therapies/32084/Several modalities are available for the treatment of multiple sclerosis relapse, including corticosteroids, intravenous immunoglobulins, and therapeutic apheresis.MS Minute: Update on BTK Inhibitors for Multiple Sclerosis—A New Treatment That Brings New Hope
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/update-on-btk-inhibitors-for-multiple-sclerosis-a-new-treatment-that-brings-new-hope/40007/BTK inhibitors are the first class of medications to slow disability progression in secondary progressive multiple sclerosis without clinical relapses.